Breast Cancer Research and Treatment

, Volume 139, Issue 2, pp 329–339

The impact of cyclin D1 overexpression on the prognosis of ER-positive breast cancers: a meta-analysis

  • Xiao-Ling Xu
  • Shu-Zheng Chen
  • Wei Chen
  • Wei-Hui Zheng
  • Xiang-Hou Xia
  • Hong-Jian Yang
  • Bo Li
  • Wei-Min Mao
Preclinical study

DOI: 10.1007/s10549-013-2563-5

Cite this article as:
Xu, XL., Chen, SZ., Chen, W. et al. Breast Cancer Res Treat (2013) 139: 329. doi:10.1007/s10549-013-2563-5

Abstract

Cyclin D1 (CCND1), a key regulator of cell cycle progression, is overexpressed in many human cancers, including breast cancer. However, the impact of CCND1 overexpression in these cancers remains unclear and controversial. We conducted a systematic literature search in PubMed and EMBASE with the search terms “cyclin D1”, “CCND1”, “breast cancer”, “prognosis”, and potential studies for analysis were selected. Studies with survival data, including progression-free survival (PFS), overall survival (OS) or metastasis-free survival (MFS), were included in this meta-analysis. A total of 33 studies containing 8,537 cases were included. The combined hazard risk (HR) and its 95 % confidence interval (CI) of OS, PFS and MFS were 1.13 (95 % CI 0.87–1.47; P = 0.35), 1.25 (95 % CI 0.95–1.64; P = 0.12), and 1.04 (95 % CI 0.80–1.36; P = 0.76), respectively, for primary breast cancer patients with tumors exhibiting CCND1 overexpression. Interestingly, the impact of CCND1 expression on OS was a 1.67-fold (95 % CI 1.38–2.02; P = 0.00) increased risk for ER-positive breast cancer patients. However, CCND1 overexpression exhibited no association with the PFS or OS of patients who received epirubicin-based neoadjuvant chemotherapy, for which the P values were 0.63 and 0.47, respectively. In summary, CCND1 overexpression impacts the prognosis of ER-positive breast cancer patients, but not patients with unselected primary breast cancer or patients treated with neoadjuvant chemotherapy.

Keywords

Cyclin D1 CCND1 Breast cancer Estrogen receptor Prognosis 

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Xiao-Ling Xu
    • 1
  • Shu-Zheng Chen
    • 2
  • Wei Chen
    • 1
  • Wei-Hui Zheng
    • 3
  • Xiang-Hou Xia
    • 3
  • Hong-Jian Yang
    • 3
  • Bo Li
    • 1
  • Wei-Min Mao
    • 1
  1. 1.Key Laboratory on Diagnosis and Treatment Technology on Thoracic CancerZhejiang Cancer Hospital (Zhejiang Cancer Research Institute)HangzhouChina
  2. 2.Department of Breast SurgeryLishui Centre HospitalLishuiChina
  3. 3.Department of Breast SurgeryZhejiang Cancer HospitalHangzhouChina

Personalised recommendations